Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it
- PMID: 29977988
- PMCID: PMC6030024
- DOI: 10.1016/j.gore.2018.04.009
Endometrial cancer in an increasingly obese population: Exploring alternative options when surgery may not cut it
Abstract
Objectives: The study objectives were to describe outcomes of obese patients with early endometrial cancer following primary non-surgical treatment, assess predictors of response, and estimate the increased surgical risk for these women.
Methods: Retrospective chart review identified women with early stage endometrial cancer at a single institution with BMI ≥ 30 kg/m2 who did not undergo surgery as primary treatment modality due to obesity and medical co-morbidities. Clinicopathologic factors were abstracted, characteristics of responders vs. non-responders compared and the National Surgical Quality Improvement Program (NSQIP) surgical risk calculator utilized to quantify surgical risks.
Results: Fifty-one patients were identified, with a mean BMI of 49.0 kg/m2. The NSQIP calculator predicted a significantly higher complication rate for our cohort compared to the expected average risk for hysterectomy (18.8% vs 7.2%, p < .0001). The majority of patients were treated with radiation alone (49%), followed by hormone therapy (45.1%). Response rates were 38.1% for women treated with hormones and 63.6% in the radiation group (p = .063). No significant differences were identified between responders and non-responders with regard to NSQIP scores, BMI, co-morbidities or age. Among those with persistent or progressive disease, 87.5% responded to secondary treatment. Only one death was from cancer progression. Two individuals died following treatment complications (one surgical, one chemotherapy); the remaining twelve deaths were due to pre-existing co-morbidities.
Conclusions: Hormone and radiation therapy are both viable options for obese patients deemed to have too significant risk of surgical complications. Pursuing surgical intervention in this population may do more harm than good.
Keywords: Endometrial cancer; Hormonal therapy; Medically inoperable; NSQIP; Obesity.
Similar articles
-
The impact of obesity on the 30-day morbidity and mortality after surgery for endometrial cancer.J Minim Invasive Gynecol. 2015 Jan;22(1):94-102. doi: 10.1016/j.jmig.2014.07.014. Epub 2014 Jul 24. J Minim Invasive Gynecol. 2015. PMID: 25064420
-
The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non-small cell lung cancer.J Thorac Cardiovasc Surg. 2016 Mar;151(3):697-705.e1. doi: 10.1016/j.jtcvs.2015.08.058. Epub 2015 Aug 24. J Thorac Cardiovasc Surg. 2016. PMID: 26410001 Free PMC article.
-
Can the American College of Surgeons Risk Calculator Predict 30-day Complications After Spine Surgery?Spine (Phila Pa 1976). 2020 May 1;45(9):621-628. doi: 10.1097/BRS.0000000000003340. Spine (Phila Pa 1976). 2020. PMID: 31770319
-
Low Albumin Levels, More Than Morbid Obesity, Are Associated With Complications After TKA.Clin Orthop Relat Res. 2015 Oct;473(10):3163-72. doi: 10.1007/s11999-015-4333-7. Epub 2015 May 21. Clin Orthop Relat Res. 2015. PMID: 25995174 Free PMC article.
-
Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.Cochrane Database Syst Rev. 2019 Aug 29;8(8):CD000329. doi: 10.1002/14651858.CD000329.pub3. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Feb 23;2:CD000329. doi: 10.1002/14651858.CD000329.pub4. PMID: 31463964 Free PMC article. Updated.
Cited by
-
The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer.Gynecol Oncol Rep. 2020 Dec 31;35:100694. doi: 10.1016/j.gore.2020.100694. eCollection 2021 Feb. Gynecol Oncol Rep. 2020. PMID: 33490354 Free PMC article.
-
Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.Brachytherapy. 2020 Jul-Aug;19(4):390-400. doi: 10.1016/j.brachy.2020.04.009. Epub 2020 May 1. Brachytherapy. 2020. PMID: 32423787 Free PMC article. No abstract available.
-
Contemporary Incidence of Medical Inoperability in Clinical Stage I Endometrial Cancer.Ann Surg Oncol. 2021 Dec;28(13):8987-8995. doi: 10.1245/s10434-021-10313-6. Epub 2021 Jun 18. Ann Surg Oncol. 2021. PMID: 34143338
-
A 10-Year Retrospective Cohort Study of Endometrial Cancer Outcomes and Associations with Lymphovascular Invasion: A Single-Center Study from Germany.Diagnostics (Basel). 2024 Aug 4;14(15):1686. doi: 10.3390/diagnostics14151686. Diagnostics (Basel). 2024. PMID: 39125562 Free PMC article.
-
Evaluation of Uterine Brachytherapy as Primary Treatment Option for Elderly Patients with Medically Inoperable Endometrial Cancer-A Single-Center Experience and Review of the Literature.Cancers (Basel). 2020 Aug 15;12(8):2301. doi: 10.3390/cancers12082301. Cancers (Basel). 2020. PMID: 32824243 Free PMC article.
References
-
- Acharya S. Medically inoperable endometrial cancer in patietns with a high body mass index (BMI): patterns of failure after 3-D image-based high dose rate (HDR) brachytherapy. Radiother. Oncol. 2016;118:167–172. - PubMed
-
- Baker W.E., Pierce S.R., Mills A.M., Gehrig P.A., Duska L.R. Nonoperative management of atypical endometrial hyperplasia and endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol. Oncol. 2017;146:34–38. - PubMed
-
- Dorais J. Fertility-sparing management of endometrial adenocarcinoma. Obstet. Gynecol. Surv. 2011;66(7):443–451. - PubMed
-
- Gunderson C.C. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol. Oncol. 2012;125(2):477–482. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources